Who Paid My Doc
Eric Bomberg
Pediatric Endocrinology Minneapolis, MN Medical Doctor
NPI 1578880746 CMS profile 1304479
2512 S 7Th St, Minneapolis, MN 55454
General payments
$60
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$122,421
Through program year 2024, Eric Bomberg of Minneapolis, MN is reported in the CMS Open Payments database as having received $60 across 1 general payment and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $122,421 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 12th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $60 | 1 |
Beside peers
- Eric Bomberg
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Eric Bomberg were reported at $0. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Eric Bomberg | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $68–$845 | $163 |
| 2020 | $0 | $124 | $37–$722 | $114 |
| 2021 | $0 | $134 | $35–$691 | $132 |
| 2022 | $0 | $177 | $47–$726 | $149 |
| 2023 | $0 | $236 | $75–$887 | $160 |
| 2024 | $60 | $259 | $91–$979 | $164 |
| 2025 | $0 | $293 | $106–$1,640 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
37
Drug cost
$1,002
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Naltrexone Hcl | Generic | 12 | $786 | |
| Fluoxetine Hcl | Generic | 11 | $125 | |
| Topiramate | Generic | 14 | $91 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Minnesota
Bradley Miller
Pediatric Endocrinology · Minneapolis, MN
Antoinette Moran
Pediatric Endocrinology · Minneapolis, MN
Mary Abuzzahab
Pediatric Endocrinology · Saint Paul, MN
Amy Criego
Pediatric Endocrinology · St Louis Park, MN
Melena Bellin
Pediatric Endocrinology · Minneapolis, MN
Ana Creo
Pediatric Endocrinology · Rochester, MN
Related records
Pediatric Endocrinology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.